应用医生自制部分微孔支架行胸主动脉腔内修复术治疗主动脉弓病变的结局
本研究纳入2017年12月至2022年6月期间56例使用医生自制部分微孔支架行胸主动脉腔内修复术的患者,评估技术成功、围术期及随访期并发症与死亡率、卒中发生率及分支动脉通畅率。中位随访18个月期间,卒中率0%、主动脉上分支通畅率100%、内漏率7.1%,无全因死亡、卒中或需开放转流。作者认为该方法是经验丰富医疗中心处理主动脉弓病变的可行选择。
要点
- 56例患者中主动脉夹层31例(55.4%)、动脉瘤10例(17.9%)、穿透性主动脉溃疡8例(14.3%)、壁内血肿7例(12.5%)。
- 中位随访18个月(四分位距13-25个月)期间卒中率0%、主动脉上分支通畅率100%、内漏率7.1%。
- 无全因死亡、卒中或需开放转流的病例。
核心结论
- 作者认为,在经验丰富的医疗中心,使用医生自制部分微孔支架行胸主动脉腔内修复术是处理主动脉弓病变的可行替代方案,表现出良好的分支通畅性、低并发症率和极低的术后死亡率。
研究设计与样本
- 本研究为单臂研究,于2017年12月至2022年6月期间收集56例使用医生自制部分微孔支架行胸主动脉腔内修复术的患者数据。
- 评估内容包括技术成功、围术期及随访期发病率与死亡率、卒中发生率及分支动脉通畅率。
主要发现
- 56例患者中男性46例,平均年龄62.1±11.2岁。
- 主动脉病变包括主动脉夹层31例(55.4%)、主动脉瘤10例(17.9%)、穿透性主动脉溃疡8例(14.3%)、壁内血肿7例(12.5%)。
- 中位随访18个月(四分位距13-25个月)期间,卒中率0%、主动脉上分支通畅率100%、内漏率7.1%。
- 无全因死亡、卒中或需开放转流的病例。
临床怎么用
- 作者认为,在经验丰富的医疗中心,使用医生自制部分微孔支架行胸主动脉腔内修复术可作为处理主动脉弓病变的可行替代方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Thoracic endovascular aortic repair (TEVAR) has been used extensively in the management of thoracic aortic diseases. Numerous efforts have been made to enhance clinical outcomes through the use of stent grafts. This study aimed to investigate the effectiveness and safety of physician-manufactured partial micropore stent grafts (PSMGs) in TEVAR. METHODS: Between December 2017 and June 2022, data were collected from 56 patients who underwent TEVAR using physician-manufactured PSMGs. The evaluation encompassed technical success, perioperative and follow-up morbidity and mortality, stroke incidence, and branch artery patency. RESULTS: In this investigation, 56 patients received treatment with physician-manufactured PSMGs. Of these patients, 46 were male, with a mean age of 62.1 ± 11.2 years. Aortic pathologies comprised aortic dissection (n = 31 [55.4%]), aortic aneurysms (n = 10 [17.9%]), penetrating aortic ulcer (n = 8 [14.3%]), and intramural hematoma (n = 7 [12.5%]). During a median follow-up of 18 months (interquartile range, 13-25 months), the stroke rate, supra-aortic branch patency rate, and endoleak rate were 0%, 100%, and 7.1%, respectively. There were no occurrences of all-cause mortality, stroke, or the necessity for open conversion. CONCLUSIONS: TEVAR with physician-manufactured PSMGs is a viable alternative for addressing aortic arch pathologies in proficient medical centers. The approach demonstrates favorable branch patency, a low complication rate, and minimal postoperative mortality.
引用
- Huang J, Tian H, Chen Z, et al. Outcomes of thoracic endovascular aortic repair with physician-manufactured partial micropore stent grafts for aortic arch pathologies. J Vasc Surg. 2023. PMID: 38157994. doi:10.1016/j.jvs.2023.12.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。